Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

NCT00516724 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

189

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Metastatic Breast Cancer
Advanced Ovarian Cancer
Carboplatin
Paclitaxel

Interventions

DRUG: KU-0059436 (AZD2281)(PARP inhibitor)
DRUG: Carboplatin
DRUG: KU-0059436 (AZD2281)(PARP inhibitor)
DRUG: Paclitaxel
DRUG: KU-0059436 (AZD2281)(PARP inhibitor)
DRUG: Paclitaxel + Carboplatin

Sponsor

AstraZeneca